Research Article
Prognosis Relevance of Serum Cytokines in Pancreatic Cancer
Table 1
Clinicopathologic characteristics of the study population (
).
| Age at diagnosis, years (mean ± StD) | 66 ± 10.5 |
| Gender | Male: 50% Female: 50% |
| Disease stage | III (28%) IV (72%) |
| Type of chemotherapy | Gemcitabine + Erlotinib |
| Clinical response | PR (14.29%) SD (21.43%) PD (64.28% |
| Survival time, months (mean ± StD) | 12.6 ± 12.6 |
| Outcome: | | Follow-up months (mean ± StD) | 12.6 ± 12.6 | Death from pancreatic cancer | 100% | Alive | 0% | Lost to follow-up (censored cases) | 0% |
| CEA level [μg/L] (mean ± StD) | 2219 ± 5017 | Healthy: 0–37 |
| CA 19-9 level [U/L] (mean ± StD) | 899 ± 3185 | Healthy: 0–5 |
|
|
PR: partial response; SD: stable disease; PD: progressive disease; StD: standard deviation.
|